At a glance
- Originator City of Hope National Medical Center; Novonco Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Teratoma
- No development reported Leukaemia